Tags : P-III STR1VE-EU Study

Novartis Reports Results of Zolgensma in P-III STR1VE-EU Study for

Shots:   The P-III STR1VE-EU study involves assessing Zolgensma (IV) in patients with SMA Type 1 aged <6mos. at the time of gene therapy, with 1 or 2 copies of the SMN2 backup gene and have bi-allelic SMN1 gene deletion or point mutations Results: 65.6% achieved motor milestones not observed in the natural history of SMA […]Read More